PetVivo (PETV) investor relations material

Market overview and product positioning

• Focus on the $11 billion companion animal veterinary care market, targeting osteoarthritis and joint issues in dogs, cats, and horses.

• Spryng with OsteoCushion technology and PrecisePRP are the main products, offering regenerative solutions and off-the-shelf convenience.

• Distribution agreements with top U.S. distributors and recent expansion into Mexico and the UK.

• Strong IP portfolio with 12 U.S. and 9 foreign patents, and ongoing expansion of intellectual property.

• Pet insurance is a growing market segment, with most treatments covered under policies.

Product differentiation and clinical results

• Spryng addresses the root cause of osteoarthritis by restoring joint mechanics, unlike competitors that only mask pain.

• Clinical studies show significant improvement in mobility and pain reduction, outperforming standard treatments.

• Over 12,000 injections performed with positive outcomes in both small animals and equine markets.

• Competitive products like Librela and Solensia require monthly injections and have reported side effects.

• Spryng offers a price-cost advantage, lasting up to a year per injection and sold exclusively to veterinary clinics.

Strategic partnerships and growth initiatives

• Partnerships with major distributors like MWI Animal Health, Covetrus, and Patterson ensure broad market reach.

• Collaborations with AI and biomembrane technology firms to enhance diagnostics and regenerative capabilities.

• Expansion into international markets, with recent entries into Mexico and the UK.

• Ongoing clinical trials at leading institutions, including Colorado State University and Ethos Veterinary Health.

• Regulatory tailwinds, such as HISA endorsement, support product adoption in equine sports.